BioCompare’s 2026 outlook brings together perspectives from across the life sciences, including insights from Abselion’s Founder & CEO, Dr. Ruizhi Wang, on the evolving needs of biologics discovery and development.
BioCompare has published “A Look Ahead: Predictions for the Life Sciences in 2026,” bringing together perspectives from researchers, tool providers and industry leaders.
The feature includes insights from Dr. Ruizhi Wang, Founder & CEO of Abselion, in the section on biologics discovery and development. Ruizhi comments on how expanding biologics pipelines and more integrated bioprocess workflows are placing greater emphasis on early analytical readouts that are fast, consistent and readily accessible to scientists across teams.
His contribution reflects Abselion’s focus on making everyday protein quantification more dependable in discovery, development and manufacturing environments.
You can read the full article on BioCompare here.